Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2010 - 2024)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Non-Current Debt came in at $4.7 million in Q4 2024, down 28.87% year-on-year from $6.6 million in Q1 2024, and down 9.76% quarter-over-quarter from $5.2 million in Q3 2024.
Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2010 - 2024) Analysis & Trends
Tonix Pharmaceuticals Holding's Non-Current Debt history runs 4 years deep, the most recent figure standing at $4.7 million for Q4 2024.
- On a quarterly basis, Non-Current Debt fell 28.87% year-over-year to $4.7 million in Q4 2024; TTM through Dec 2024 was $4.7 million, a 28.87% decrease from a year earlier, with the FY2024 full-year figure at $4.7 million, down 28.87% from the prior year.
- Non-Current Debt retreated to $4.7 million in Q4 2024 per TNXP's latest filing, from $5.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $6.6 million in Q4 2023 and bottomed at $4.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.67 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.67 Mn |
| Mar 31, 2024 | 6.16 Mn |
| Dec 31, 2023 | 6.56 Mn |
| Jun 30, 2011 | 10,000.00 |
| Dec 31, 2010 | 10,000.00 |